Pregnancy and the Postpartum Period in Hodgkin Lymphoma: Impact on Disease Outcomes and Infectious Risk—A Multicenter Retrospective Study
Background/Objectives: Hodgkin lymphoma (HL) is the most common hematological malignancy among women of reproductive age. However, data on disease outcomes and infectious complications in pregnancy-associated HL are limited. No prior study has examined patients treated exclusively in the postpartum period. Our objective was to assess whether pregnancy-associated HL is associated with poorer disease outcomes and an increased risk of infectious complications. Methods: A multicenter, retrospective matched cohort study included 13 women diagnosed with HL during pregnancy or within 12 months postpartum (pregnancy-associated, PA) and 22 matched non-pregnancy-associated (NPA) controls. Controls were matched by International Prognostic Score, Ann Arbor stage, and age (within ±5 years), with diagnoses made between 2016 and 2025. Conditional logistic regression and mixed-effects Poisson regression were used to analyze infectious episodes separately for first-line and subsequent treatments. Progression-free survival (PFS) was estimated using the Kaplan–Meier method. Results: During first-line therapy, the PA group demonstrated significantly higher odds of any infection (OR 5.47, 95% CI 1.11–26.88, p = 0.037) and a higher number of infectious episodes (IRR 3.11, 95% CI 1.73–5.62, p < 0.001). No statistically significant differences were observed during subsequent lines of treatment. Progressive disease following first-line therapy was more frequent in the PA group (38.5% vs. 9.1%, p = 0.0559). Progression-free survival (PFS) at 12 months was 52.7% (95% CI 19.0–78.2) in the PA group compared to 77.3% (95% CI 53.7–89.8) in the NPA group (log-rank p = 0.27). No deaths were reported in either group. Conclusions: Pregnancy-associated HL is linked to a higher risk of infectious complications during first-line treatment and an increased rate of primary progression. These findings support the need for closer infectious surveillance in this population and should be confirmed in larger cohorts.
Authors
- Sorina Nicoleta BADELITA (ORCID: https://orcid.org/0000-0002-1507-2547)
- Camelia Marioara Dobrea (ORCID: https://orcid.org/0000-0003-0607-8573)
- Andra Matei
- Daniel Coriu (ORCID: https://orcid.org/0000-0002-7251-6079)
- Daniel Nicolae MURARIU (ORCID: https://orcid.org/0009-0004-3208-2108)
- Iulia Ursuleac
- Oana Diana Preda
- Larisa Emilia Zidaru (ORCID: https://orcid.org/0009-0007-3278-9260)
- Simona Raluca Iacoban (ORCID: https://orcid.org/0009-0008-7125-7758)
- Sanziana BARBU
- Bianca CONSTANTIN (ORCID: https://orcid.org/0009-0000-7491-3054)
- Andreea-Lacramioara Mohorea-Neata (ORCID: https://orcid.org/0009-0006-1708-1128)
- Bianca TARAU (ORCID: https://orcid.org/0009-0006-7050-4070)
- Ioana Loredana Cirlan
- Florentina-Adriana Găuianu
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Medicover (DE)
- Institutul Clinic Fundeni (RO)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3390/jcm15228884
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00